INmune Bio surges after XPro1595 showed efficacy in decreasing neuroinflammation in Alzheimer's patients Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Karyopharm (KPTI) up 7% after reporting preliminary Q2 Xpovio sales of $18.5M
- Tesla (TSLA) up 5% after Piper Sandler analyst Alexander Potter raised the firm's price target to $2,322 from $939 and kept an Overweight rating on the shares
- Fitbit (FIT) up 3% after Reuters reported Google (GOOG) has offered not to use the company's health data to help it target ads in an effort to assuage EU antitrust worries about the proposed $2.1B acquisition of the company
- Hanesbrands (HBI) up 5% after Credit Suisse analyst Michael Binetti upgraded the stock to Outperform from Neutral with a price target of $15, up from $13
- INmune Bio (INMB) up 124% after reporting clinical data demonstrating that its lead drug candidate, XPro1595, decreases neuroinflammation in patients with Alzheimer's disease
LOWER -
- Equillium (EQ) down 31% after filing $150M common stock sales agreement with Jefferies
- Verrica Pharmaceuticals (VRCA) down 14% after receiving a Complete Response Letter from the FDA regarding the NDA for VP-102
- Spotify (SPOT) down 3% after UBS analyst Eric Sheridan double-downgraded shares to Sell from Buy with a price target of $204, up from $189
- Osmotica Pharmaceuticals (OSMT) down 18% after its 5M share spot secondary offering priced at $6.55 per share
BANKS AFTER EARNINGS -
- JPMorgan (JPM) up 1%
- Wells Fargo (WFC) down 4%
- Citi (C) down 1%
Symbols:
KPTI TSLA - $1,493.85 /
-53.69 (-3.47%)
FIT HBI INMB EQ - $27.05 /
+23.95 (+772.58%)
VRCA SPOT - $261.11 /
-17.08 (-6.14%)
OSMT JPM C WFC Keywords: Fly Intel, Wall Street, Top Stories, Stocks